NLS Pharmaceutics AG
NLSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 1.19 | -16.62 | -1.47 |
| FCF Yield | -268.86% | -1.08% | -1.37% | -2.29% |
| EV / EBITDA | 0.02 | -76.18 | -65.07 | -54.80 |
| Quality | ||||
| ROIC | -311.45% | 265.97% | -261.66% | -352.86% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 2.15 | 0.80 | 0.84 | 1.25 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 55.89% | 30.22% | 7.32% | -1,953.18% |
| Safety | ||||
| Net Debt / EBITDA | 0.46 | -0.06 | 0.58 | 0.46 |
| Interest Coverage | -29.20 | -81.34 | -153.49 | -174.08 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.28 | -0.26 |
| Cash Conversion Cycle | -56,655.34 | -148,250.34 | -77,252.76 | -64,485.66 |